hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06360809 id: 2024 PARINEFC 00001 briefTitle: Prehabilitation Exercise Program in Breast Cancer: Effects on Quality of Life and Tumor Microenvironment (PEP_BC) acronym: PEP_BC overallStatus: RECRUITING date: 2024-03-22 date: 2025-06 date: 2025-06 date: 2024-04-11 date: 2024-04-11 name: Institut Nacional d'Educacio Fisica de Catalunya class: OTHER name: ICFO - The Institute of Photonics Sciences name: Hospital Clinic of Barcelona name: Institut d'Investigacions Biomèdiques August Pi i Sunyer name: Universidad San Jorge briefSummary: To improve the health and quality of life of breast cancer (BC) patients, researchers are focusing on prehabilitation strategies like physical exercise, preparing patients both mentally and physically for clinical and surgical procedures, potentially reducing complications. Physical exercise is also recognized as pivotal in optimizing chemotherapy. It can improve blood flow and oxygen supply in the microenvironment of the tumor (MT), potentially enhancing chemotherapy effectiveness. Although previous research has shown the benefits of preoperative exercise combined with chemotherapy in various cancer types, including BC, further investigation is needed into the exact effects of prehabilitation exercise (PE) on MT physiology.
This study aims to provide valuable insights into the potential benefits of PE for BC patients and its impact on the tumor microenvironment. The hypothesis is that PE in BC patients will improve their quality of life, reduce fatigue, increase muscle mass, decrease fat mass, and enhance physical fitness. Additionally, beneficial acute hemodynamic changes, particularly increased blood flow following PE sessions, and hemodynamic adaptations involving higher levels of oxygenated hemoglobin, increased blood flow, greater oxygen saturation, and a higher metabolic rate of oxygen, are expected.
nctId: NCT06360796 id: 2023-ADC189-I-010 briefTitle: Study of Pharmacokinetics and Metabolism on [(14)C]ADC189 overallStatus: RECRUITING date: 2023-11-24 date: 2024-06-30 date: 2024-07-30 date: 2024-04-11 date: 2024-04-11 name: Jiaxing AnDiCon Biotech Co.,Ltd class: INDUSTRY briefSummary: This study is designed to determined the metabolism, excretion, and substance balance of almonertinib of ADC189. The pharmacokinetic characteristics and safety profile of ADC189 was investigated following a single oral dose (45 mg/100 µCi) in healthy Chinese male participants. conditions: Pharmacokinetics conditions: Metabolism studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 6 type: ESTIMATED name: [(14)C]ADC189 measure: The Area Under the Curve (AUC) of [(14)C]ADC189 and its metabolites measure: The Maximum Plasma Concentration [Cmax] of [(14)C]ADC189 and its metabolites measure: The whole blood and serum concentrations of total radioactivity of [(14)C]ADC189 (about 100 μCi) measure: The urinary and fecal recovery of total radioactivity of [(14)C]ADC189 (about 100 μCi) sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: The First Affilicated Hospital of Bengbu Medical University status: RECRUITING city: Bengbu state: Anhui zip: 233004 country: China name: Huan Zhou role: CONTACT phone: +8613665527160 email: zhouhuanbest@vip.163.com lat: 32.94083 lon: 117.36083 hasResults: False
nctId: NCT06360783 id: Pro00111388 briefTitle: COVID-19 Quick Start - Test and Treat in Africa overallStatus: ACTIVE_NOT_RECRUITING date: 2023-02-01 date: 2024-06 date: 2024-06 date: 2024-04-11 date: 2024-04-26 name: Duke University class: OTHER name: Duke Clinical Research Institute name: Clinton Health Access Initiative, Nigeria briefSummary: Duke University and the Clinton Health Access Initiative (CHAI), in partnership with the Ministries of Health (MoH) of Ghana, Malawi, Rwanda, Zambia, and Zimbabwe, aim to assess the implementation and impact of COVID-19 test -and -treat (T\&T) demonstration programs conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED measure: Stakeholder Perspectives sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke Global Health Institute city: Durham state: North Carolina zip: 27705 country: United States lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06360770 id: NIRSCovidSBCelje briefTitle: Assessement of Microcirculation With NIRS Predicts Sepsis Development in Patients With Severe Covid-19 Pneumonia overallStatus: COMPLETED date: 2021-12-01 date: 2023-02-28 date: 2023-04-30 date: 2024-04-11 date: 2024-04-12 name: General and Teaching Hospital Celje class: OTHER briefSummary: Sepsis and septic shock are among main causes of death in patients with severe Covid-19 pneumonia. A few factors are proven to predict sepsis in these patients. WIth near infrared spectroscopy it is possible to detect microcirculatory changes typical for sepsis early in the course of disease. The hypothesis that changes in tissue oxygene saturation during vasoocclusive test predict sepsis as well as mortality in mechancally ventilated patients withe severe Covid-19 pneumonia will be tested. conditions: Sepsis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 35 type: ACTUAL measure: sepsis development measure: mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SB Celje city: Celje zip: 3000 country: Slovenia lat: 46.23092 lon: 15.26044 hasResults: False
nctId: NCT06360757 id: DHF-21-2141-1 briefTitle: Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19) overallStatus: RECRUITING date: 2024-02-06 date: 2024-09-01 date: 2024-09-01 date: 2024-04-11 date: 2024-04-11 name: QIAGEN Gaithersburg, Inc class: INDUSTRY briefSummary: A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19 infection. This study will evaluate the NeuMoDx SARS-CoV-2 Assay's clinical performance on the NeuMoDx 288 and NeuMoDx 96 Molecular Systems. conditions: SARS-CoV-2 Acute Respiratory Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 1432 type: ESTIMATED name: NeuMoDx SARS-CoV-2 Assay measure: Sensitivity as compared to the comparator method measure: Specificity sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: QIAGEN Gaithersburg, Inc status: RECRUITING city: Manchester zip: M130BH country: United Kingdom name: Sarah G Johnson role: CONTACT phone: 44 7825866041 email: Sarah.Johnson@qiagen.com name: Helen Green role: CONTACT phone: 44 7825866041 email: Helen.Green@qiagen.com lat: 53.48095 lon: -2.23743 hasResults: False
nctId: NCT06360744 id: ENFORCE PLUS briefTitle: A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines. overallStatus: COMPLETED date: 2021-07-05 date: 2023-12-31 date: 2023-12-31 date: 2024-04-11 date: 2024-04-11 name: Jens D Lundgren, MD class: OTHER name: Ministry of the Interior and Health, Denmark briefSummary: A phase IV study to assess if the SARS-CoV-2 vaccine from Johnson \& Johnson/Janssen (J\&J) results in change in number and activation of platelets and anti-PF4 Level. As well as compare whether the vaccine is causing a greater activation of platelets and anti-PF4 than the mRNA vaccines.
The design is an open-labelled, non-randomised, parallel group, phase IV study with historical controls. A sub-study will be embedded within this master protocol addressing basic and translational research questions requiring additional sampling of biological material (under separate participant informed consent). conditions: SARS CoV 2 Infection studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The design is an open-labelled, non-randomised, parallel group, phase IV study with historical controls. primaryPurpose: OTHER masking: NONE count: 25 type: ACTUAL name: Johnson & Johnson measure: Assessment of the J& J vaccine sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aarhus Universitetshospital, Skejby city: Aarhus state: Aarhus N zip: 8200 country: Denmark lat: 56.15674 lon: 10.21076 facility: Aalborg Universitetshospital Syd city: Aalborg zip: 8000 country: Denmark lat: 57.048 lon: 9.9187 facility: Hvidovre Hospital city: Hvidovre zip: 2600 country: Denmark lat: 55.65719 lon: 12.47364 facility: Odense Universitetshospital city: Odense zip: 5000 country: Denmark lat: 55.39594 lon: 10.38831 facility: Sjællandsuniversitetshospital city: Roskilde zip: 4000 country: Denmark lat: 55.64152 lon: 12.08035 hasResults: False
nctId: NCT06360731 id: 1018 briefTitle: The Effect of 4-7-8 Breathing Exercise Technique on Tinnitus overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-18 date: 2024-05-31 date: 2024-05-31 date: 2024-04-11 date: 2024-04-23 name: Ege University class: OTHER briefSummary: The goal of this study is to evaluate the effect of 4-7-8 breathing exercise on tinnitus handicap, psychological factors and sleep quality.
Both groups will receive 1 hour of informative session on tinnitus and the experimental group will also perform 4-7-8 breathing exercises for 6 weeks. Visual analog scale, tinnitus handicap inventory, insomnia severity index, trait anxiety inventory, and perceived stress scale will be applied before and after the application. conditions: Tinnitus, Subjective studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study employs a parallel group randomised controlled trial design. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: In the study, patients do not know which group they were in. Therefore, blinding is performed among the participants. To prevent bias in the study, blinding is also performed between the researchers. Researchers (S.B. and A.O. from both clinics) make the pre- and post-test evaluations without knowing which group the patients are in. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ACTUAL name: 4-7-8 breathing exercise technique and informative session on tinnitus name: Informative session on tinnitus measure: Visual Analog Scale (VAS) measure: Visual Analog Scale (VAS) measure: Tinnitus Handicap Inventory (THI) measure: Tinnitus Handicap Inventory (THI) measure: Insomnia severity index (ISI) measure: Insomnia severity index (ISI) measure: Perceived stress scale -10 (PSS-10) measure: Perceived stress scale -10 (PSS-10) measure: Trait Anxiety Scale (TAS) measure: Trait Anxiety Scale (TAS) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gokce Saygi Uysal city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 facility: Audiology Unit of the Department of Otorhinolaryngology, Ege University Faculty of Medicine Hospital city: Izmir country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06360718 id: CHLA-23-00170 briefTitle: Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress. overallStatus: RECRUITING date: 2024-02-03 date: 2025-05-15 date: 2025-05-15 date: 2024-04-11 date: 2024-04-19 name: Children's Hospital Los Angeles class: OTHER briefSummary: The goal of this clinical trial is to measure the effects of using a storybook versus standard child life intervention with parents of children newly diagnosed with leukemia on parental stress.
Researchers will compare Intervention and Control Groups to see if parental stress is lower in those who received the storybook in addition to the standard child life intervention versus the standard child life intervention alone. conditions: Leukemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 140 type: ESTIMATED name: "Who is Luke Eemia?" Storybook measure: Parental Stress, prior to and following child life intervention measure: Parent perception of the child's stress measure: Parent's Comfort Explaining Aspects of Leukemia Diagnosis measure: Parent comfort, readiness, and importance, explaining aspects of the diagnosis at the discharge (1-week post baseline). measure: Parental Impression of the Storybook Tool using a Likert scale (1-week post baseline). sex: ALL minimumAge: 3 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Children's Hospital Los Angeles status: RECRUITING city: Los Angeles state: California zip: 90027 country: United States name: Erin Shields, MA role: CONTACT lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06360705 id: CVVD003 briefTitle: StrataMGT for the Treatment of Vulvar Lichen Sclerosus overallStatus: RECRUITING date: 2024-04 date: 2024-09 date: 2024-10 date: 2024-04-11 date: 2024-04-19 name: Center for Vulvovaginal Disorders class: OTHER name: Stratpharma AG briefSummary: This study is designed to evaluate the efficacy and safety of StrataMGT for the treatment of vulvar lichen sclerosus. conditions: Vulvar Lichen Sclerosus studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 5 type: ESTIMATED name: StrataMGT measure: Histopathologic Inflammation sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centers for Vulvovaginal Disorders status: RECRUITING city: New York state: New York zip: 10036 country: United States name: Andrew Goldstein, MD role: CONTACT phone: 4102790209 email: obstetrics@yahoo.com name: Andrew Goldstein, MD role: PRINCIPAL_INVESTIGATOR name: Leia Mitchell, PA-C, MMSc, MSc role: SUB_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06360692 id: Marta Lluesma Vidal Carden briefTitle: Impact of Nipple Micropigmentation in Mastectomized Women overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-10-30 date: 2025-12-31 date: 2024-04-11 date: 2024-04-11 name: Cardenal Herrera University class: OTHER briefSummary: This will be a multicenter prospective descriptive case series study following a cohort.
CAP micropigmentation/tattooing is usually performed between 6 and 12 months after the breast reconstructive surgery has been completed, sufficient time for healing to complete and the breast to stabilize, although it can be performed from 2 months after the intervention. Nurses are responsible for performing micropigmentation/tattooing of the areola and nipple in mastectomized women. conditions: Body Image conditions: Female Sexual Function conditions: Self Esteem conditions: Intimacy With Your Partner studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: Body imagen measure: Self-esteem measure: Sexual Function measure: Intimacy with the partner sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06360679 id: CIP000004 briefTitle: Clinical Feasibility Study of the BariTon™ System in Obese or Overweight Patients. overallStatus: RECRUITING date: 2024-01-29 date: 2024-10-01 date: 2025-06-01 date: 2024-04-11 date: 2024-04-11 name: BariaTek Medical class: INDUSTRY briefSummary: Safety and efficacy evaluation of the BariTon™, BariaTek Medical gastric restriction and biliodigestive diversion device. conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Endoscopic gastric restriction and biliodigestive diversion measure: Safety of the BariTon™ measure: Safety of the BariTon™ measure: Safety of the BariTon™ measure: Safety of the BariTon™ measure: Efficacy of the BariTon™ measure: Efficacy of the BariTon™ measure: Efficacy of the BariTon™ measure: Efficacy of the BariTon™ measure: Efficacy of the BariTon™ measure: Efficacy of the BariTon™ sex: ALL minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT facility: BMI Clinic Double Bay status: RECRUITING city: Sydney state: New South Wales zip: 2028 country: Australia name: Adrian Sartoretto, Dr role: CONTACT phone: 0290534688 phoneExt: 61 email: info@bmiclinic.com.au lat: -33.86785 lon: 151.20732 facility: BMI Clinic Liverpool status: RECRUITING city: Sydney state: New South Wales zip: 2170 country: Australia name: Adrian Sartoretto, Dr role: CONTACT phone: 0290534688 phoneExt: 61 email: info@bmiclinic.com.au lat: -33.86785 lon: 151.20732 hasResults: False
nctId: NCT06360666 id: Neurax1 briefTitle: Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia acronym: NEURAX overallStatus: ENROLLING_BY_INVITATION date: 2022-10-01 date: 2024-01-31 date: 2024-12-31 date: 2024-04-11 date: 2024-04-11 name: Asst Melegnano e Martesana class: OTHER_GOV briefSummary: The goal of this observational study is to learn about postoperative mortality and postoperative length of stay outcomes after abdominal laparoscopic major surgery. The main question it aims to answer is:
Does general anesthesia lower complications compared to loco-regional anesthesia (keeping the patient spontaneously breathing and sedated) in laparoscopic abdominal major surgery? Participants are followed for neurological sequelae for 90 days following surgery conditions: Mortality conditions: Surgical Complication conditions: Neurological Complication conditions: Respiratory Complication conditions: Cardiovascular Complication conditions: Nephrotoxicity conditions: Metabolic Complication studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 70 type: ESTIMATED measure: Mortality measure: Morbidity measure: Surgical revisions measure: organ dysfunctions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ASST Melegnano e Martesana - Ospedale Vizzolo Predabissi city: Vizzolo Predabissi state: Milan zip: 20070 country: Italy lat: 45.35587 lon: 9.34815 hasResults: False
nctId: NCT06360653 id: 76CIVICO2023 briefTitle: a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer acronym: SISTER-RAY overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2026-06 date: 2024-04-11 date: 2024-04-11 name: ARNAS Civico Di Cristina Benfratelli Hospital class: OTHER briefSummary: The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer conditions: Endometrial Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Stereotactic Post-operative Radiotherapy for Endometrial Cancer measure: Acute G3 or higher Gastrointestinal and Genitourinary Toxicity measure: Late Gastrointestinal and Genitourinary Toxicity measure: Distant Progression Free Survival measure: Local Control measure: Overall Survival measure: Overall Quality of Life sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ARNAS Civico Hospital city: Palermo state: PA zip: 90100 country: Italy name: FRANCESCO CUCCIA, MD role: CONTACT phone: +393334393336 email: francesco.cuccia@arnascivico.it lat: 38.13205 lon: 13.33561 hasResults: False
nctId: NCT06360640 id: APC148-001 id: 2023-507939-38-00 type: OTHER domain: EU Trial no briefTitle: A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-03 date: 2025-03 date: 2024-04-11 date: 2024-04-11 name: AdjuTec Pharma AS class: INDUSTRY name: CTC Clinical Trial Consultants AB briefSummary: The purpose of this first-in-human trial is to investigate the safety, tolerability, and pharmacokinetics of APC148 after intravenous (IV) infusion of single ascending doses in healthy adults. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Placebo-controlled, 6 sequential cohorts. primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: This is a double-blind trial. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 46 type: ESTIMATED name: APC148 and Placebo measure: Incidence and intensity of adverse events (AEs) measure: Incidence and intensity of serious adverse events (SAEs) measure: Incidence and intensity of infusion-related AEs measure: Time course of local tolerability reactions measure: Changes from baseline in blood pressure measure: Changes from baseline in respiratory rate measure: Changes from baseline in body temperature measure: Changes from baseline in heart rate measure: Changes from baseline in PQ/PR interval measure: Changes from baseline in QRS interval measure: Changes from baseline in QT interval measure: Changes from baseline in QTcF interval measure: Changes from baseline in Clinical Laboratory Profile measure: Changes from baseline in physical examination measure: APC148 plasma concentrations measure: APC148 urine concentrations measure: Pharmacokinetic (PK) parameter in plasma - Area under curve (AUC) 0-24 measure: PK parameter in plasma - AUC0-inf measure: PK parameter in plasma - AUC0-last measure: PK parameter in plasma - Cmax measure: PK parameter in plasma - Tmax measure: PK parameter in plasma - T1/2 measure: PK parameter in plasma - Clearance (CL) measure: PK parameter in plasma - Vz measure: PK parameter in plasma - Vss determination of plasma concentrations will be collected. measure: PK parameters in urine - A(e) measure: PK parameters in urine - fe measure: PK parameter in urine - renal clearance (CLr) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Clinical Trial Consultants AB city: Uppsala country: Sweden name: Erik Rein-Hedin, MD role: PRINCIPAL_INVESTIGATOR lat: 59.85882 lon: 17.63889 hasResults: False
nctId: NCT06360627 id: 2022_D0008 briefTitle: Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT overallStatus: RECRUITING date: 2023-02-20 date: 2027-03-31 date: 2027-12-01 date: 2024-04-11 date: 2024-04-11 name: University of Zurich class: OTHER briefSummary: Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT conditions: Radiation Exposure conditions: Lung Embolism conditions: Lung Cancer conditions: Pneumonia studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Computed Tomography measure: Dose Reduction by new scanner measure: stable Image Quality in reduced dose scans sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Zurich - Diagnostic Radiology status: RECRUITING city: Zurich zip: 8091 country: Switzerland name: Thomas Frauenfelder, PD MD role: CONTACT phone: 0041442551111 email: thomas.frauenfelder@usz.ch name: Marga Rominger, Prof MD role: CONTACT phone: 0041442551111 email: marga.rominger@usz.ch name: Thomas Frauenfelder, PD MD role: PRINCIPAL_INVESTIGATOR lat: 47.36667 lon: 8.54999 hasResults: False